Page 298

House Bill No. 5506

Public Act No. 22-118 298 of 739

substance in the appropriate schedule: (1) 1-pentyl-3-(1-naphthoyl)indole (JWH-018); (2) 1-butyl-3-(1-naphthoyl)indole (JWH-073); (3) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); (4) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497); (5) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol; CP-47,497 C8 homologue); (6) Salvia divinorum; and (7) Salvinorum A. [(j)] (k) Notwithstanding the provisions of subsection (c) of this section, the Commissioner of Consumer Protection shall designate the following substances, by whatever official, common, usual, chemical or trade name designation, as controlled substances in schedule I of the controlled substances scheduling regulations: (1) Mephedrone (4-methylmethcathinone); and (2) MDPV (3,4-methyenedioxypyrovalerone). Sec. 203. (NEW) (Effective July 1, 2022) The Department of Consumer Protection shall consider for adoption any nonbinding federal guidelines from the federal Department of Health and Human Services regarding the practice of psychedelic-assisted therapy. The Connecticut Psychedelic Treatment Advisory Board established under section 201 of this act and members of the public may submit written comments to the department during a notice and comment period established by the department regarding adoption of and any suggested changes to such